Mentor
This article was originally published in The Gray Sheet
Executive Summary
A determination as to whether the breast implant maker may have violated federal securities laws is requested by House Commerce Committee Chairman Thomas Bliley in an April 3 letter to the Securities and Exchange Commission Enforcement Division. The issue relates to a recent Mentor public statement denying the firm is the subject of a criminal investigation by FDA based on "allegations of serious irregularities in breast implant studies" (1"The Gray Sheet" March 27, p. 14). Mentor has publicly denied the investigation is based on these particular allegations, contradicting FDA assertions. Bliley made the request since Mentor's denial apparently caused the firm's stock to rebound sharply after initially falling up to 50% upon an initial news report in the March 23 USA Today. FDA's General and Plastic Surgery Devices Advisory Panel recommended at a March 1 meeting that Mentor's saline filled breast implants should remain on the market (2"The Gray Sheet" March 6, p. 3). FDA has indicated that it will make its decision on Mentor's PMA by May 12
You may also be interested in...
Mentor Investigation Does Not Involve Breast Implant PMA Data, Firm Says
Conversations between Mentor Corp. and FDA's Office of Criminal Investigations have not "related in any way to our research or our [clinical] studies" of saline-filled breast implants, Mentor President and CEO Anthony Gette reported at a March 23 teleconference.
Mentor, Inamed Saline Breast Implants Deemed Approvable By FDA Panel
Saline breast implants manufactured by Mentor Corp. and Inamed Corp. should remain on the U.S. market provided the device manufacturers beef up labeling and physician training to help insure that patients are fully informed of any possible adverse outcomes, FDA's General and Plastic Surgery Devices Advisory Panel recommended at a March 1 meeting in Gaithersburg, Maryland.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.